What Is Corporate Venture Capital? History & Market | Breslin AG

Private Equity Insights

What Is Corporate Venture Capital? A Short History and How the Market Evolved

Corporate venture capital (CVC) has moved from the margins of corporate strategy to its centre. When a corporation takes a minority equity stake in an external start-up — typically a young, high-growth business operating at the edge of the parent’s industry — it is practising corporate venture capital. The aim is rarely financial return alone. CVC is the instrument through which an incumbent buys a structured window onto the technologies, business models and talent that may define its market a decade from now.

This four-part series sets out what corporate venture capital is, what it accomplishes, where the capital is flowing, and how the discipline is changing. We begin with the foundations: a clear definition, a short history, and a view of the market as it stands in 2026.

In this environment, European private markets — accessed via secondaries at a discount to NAV — still represent a structurally compelling proposition for dollar-based allocators. 

What corporate venture capital actually is

At its simplest, CVC is venture investing carried out by a non-financial corporation rather than a dedicated venture fund. The distinction matters. A traditional venture capital firm answers to limited partners and is measured almost entirely on financial return. A corporate venture investor answers to a parent company and is judged on two axes at once: financial performance and strategic contribution — access to new technology, early sight of acquisition targets, commercial partnerships, and a clearer reading of where an industry is heading.

That dual mandate shapes everything about how CVC operates. Capital may sit on the corporate balance sheet or in a ring-fenced fund. Investment horizons are often longer and more patient than a classic fund’s ten-year clock, because the strategic value of a portfolio company can outlast any single financing round. And the definition of a good outcome is broader: a deal that never produces a headline return can still be a success if it accelerates the parent’s research, opens a market, or de-risks a future acquisition.

It is worth distinguishing corporate venture capital from the adjacent tools it is often confused with. An accelerator or incubator nurtures very early companies, usually without a meaningful equity thesis; venture building creates companies from scratch inside the parent; and venture clienting buys from start-ups without taking equity at all. CVC is specifically the practice of taking minority equity positions in independent companies — close enough to learn from and to influence, but far enough to let the entrepreneur run. That balance is the source of both its appeal and its difficulty.

A short history of corporate venture capital

Corporate venturing is older than most assume. The first systematic programmes appeared in the 1960s, when American industrial giants — DuPont, 3M, Dow Chemical and others — began making minority investments in young technology companies. Xerox ran an active corporate fund from the same decade. This first wave was largely over by the mid-1970s; the average programme of that era lasted only about four years, and a 1969 increase in US capital-gains tax cooled the wider venture market.

The arrival of the personal computer at the end of the 1970s triggered a second wave. The number of active corporate investors climbed from fewer than fifty in the mid-1970s to more than 250 by the mid-1980s. A third wave accompanied the internet boom of the late 1990s, and a fourth — by far the largest and most durable — has run from the early 2010s to today. Each wave has been pro-cyclical, expanding in buoyant markets and contracting in downturns. What is different about the current era is that corporate venturing has not retreated between cycles; it has become a standing feature of corporate strategy.

The corporate venture capital market today

The scale is now considerable. Global venture funding reached roughly half a trillion dollars in 2025 — its second-highest annual total on record — and corporate investors were involved across a large share of it. Industry trackers estimate that more than 3,000 corporations made at least one minority investment in a start-up over the past year, that over 1,400 corporate venture funds are actively deploying capital, and that more than 40% of the world’s largest companies now run a dedicated CVC unit. Median corporate venture deal sizes have risen to around $10 million as programmes concentrate on fewer, larger, more strategic bets.

Europe is a meaningful part of this picture. In 2025 the DACH region — Germany, Austria and Switzerland — overtook the UK and Ireland to become the largest European venture-fundraising geography. Rounds that include a corporate or strategic investor have commanded a notable premium over VC-only rounds at the same stage, reflecting how much incumbents will pay for early access to relevant technology.

How corporate venturing has evolved

The trajectory is from opportunism to discipline. Early programmes were often experimental, loosely governed and quick to be wound down when budgets tightened. Modern corporate venture units look very different: professionalised teams, clearer strategic theses, defined governance, and tight integration with corporate development and M&A. CVC is increasingly treated not as a side-bet but as the front end of an innovation pipeline that runs through partnership and, frequently, to acquisition.

That maturity has also surfaced the harder questions — how to structure a programme, how to keep incentives aligned with both the parent and the portfolio company, and crucially how to realise value when strategy shifts and a holding is no longer core. Those questions are the subject of the rest of this series.

Breslin has advised corporates, banks and venture investors on their innovation portfolios for more than 26 years, with deep roots in life sciences and industrial technology. In Part 2 we turn to what corporate venture capital is actually for.

Discuss a portfolio sale with Breslin

If you hold PE assets and are exploring a secondary sale, the Breslin team will run a confidential assessment – portfolio benchmarking, indicative discount ranges and a recommended process architecture – before any commitment.

 

Get in touch

Next in the series — Part 2: What Corporate Venture Capital Accomplishes.

part-01_forest-night@2x
What Is Corporate Venture Capital? A Short History and How the Market Evolved - THE CORPORATE VENTURE SERIES · PART 1 OF 4
Corporate venture capital explained: what CVC is, how it evolved from the 1960s into a $500bn+ market,...
Read More
06_warm-overcast@2x
European Private Equity Secondaries: Macro Trends, Interest Rates and Investment Opportunities in 2026
Higher US yields, a stronger euro and ECB-Fed divergence are reshaping private equity and venture allocation....
Read More
05_midnight-skyline@2x
Private Equity in DACH Pensions: Caps, Allocators and the Secondary Market
A practical view on how Swiss and German pension funds engage with private equity, the quantitative caps...
Read More
02_facade-daylight@2x
Secondary Market Discounts in DACH: Securing the Best Return on Non-Cyclical, Industrial, Life Science and Energy Portfolios
How DACH sellers of Non-Cyclical, Industrial, Life Science and Energy portfolios can minimise secondary...
Read More
05_midnight-skyline@2x
Secondary Market Opportunities for DACH Insurers
DACH insurers are reviewing private equity holdings in healthcare, life sciences, pharma, agri and technology....
Read More
03_skyline-goldenhour@2x
LP and GP Secondary Market Strategies in 2026: Trends, Pricing and What's Changed​
Private equity secondaries in 2026 are being reshaped by tighter pricing, more sophisticated GP-led deals,...
Read More
04_pale-facade@2x
Private Equity Secondary Market Explained: LP & GP Guide (2026)​
From LP portfolio sales to GP-led continuation vehicles, this article breaks down how the private equity...
Read More
Scroll to Top